tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI
US Market
DNLI
Denali Therapeutics
RESEARCH TOOLSreports
Want to see DNLI full AI Analyst Report?

Denali Therapeutics (DNLI) Stock Forecast & Price Target

879 Followers
See the Price Targets and Ratings of:

DNLI Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Denali
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DNLI Stock 12 Month Forecast

Average Price Target

$36.27
▲(76.34% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $36.27 with a high forecast of $42.00 and a low forecast of $30.00. The average price target represents a 76.34% change from the last price of $20.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","19":"$19","27":"$27","35":"$35","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.27272727272727,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,19,27,35,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.68,21.396923076923077,23.113846153846154,24.83076923076923,26.54769230769231,28.264615384615382,29.981538461538463,31.698461538461537,33.41538461538462,35.13230769230769,36.84923076923077,38.566153846153846,40.28307692307692,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.68,20.956363636363637,22.232727272727274,23.509090909090908,24.785454545454545,26.061818181818182,27.338181818181816,28.614545454545453,29.89090909090909,31.167272727272728,32.443636363636365,33.72,34.99636363636364,{"y":36.27272727272727,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.68,20.473846153846154,21.267692307692307,22.06153846153846,22.855384615384615,23.64923076923077,24.443076923076923,25.236923076923077,26.03076923076923,26.824615384615385,27.61846153846154,28.412307692307692,29.206153846153846,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$42.00Average Price Target$36.27Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DNLI
Charles Moore
Robert W. Baird
Robert W. Baird
$32→$34
Buy
65.29%
Upside
Reiterated
04/07/26
Denali Therapeutics price target raised to $34 from $32 at BairdDenali Therapeutics price target raised to $34 from $32 at Baird
H.C. Wainwright Analyst forecast on DNLI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$95→$42
Buy
104.18%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Fennec Pharmaceuticals (NASDAQ: FENC)
BTIG Analyst forecast on DNLI
Thomas Shrader
BTIG
BTIG
$38→$39
Buy
89.60%
Upside
Assigned
04/06/26
Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
Stifel Nicolaus Analyst forecast on DNLI
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$34→$41
Buy
99.32%
Upside
Reiterated
03/29/26
Stifel Nicolaus Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
Jefferies Analyst forecast on DNLI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$40
Buy
94.46%
Upside
Reiterated
03/26/26
Jefferies Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
Wedbush Analyst forecast on DNLI
Laura Chico
Wedbush
Wedbush
$30
Buy
45.84%
Upside
Reiterated
03/26/26
Wedbush Remains a Buy on Denali Therapeutics (DNLI)
Deutsche Bank Analyst forecast on DNLI
David Hoang
Deutsche Bank
Deutsche Bank
$26→$35
Buy
70.15%
Upside
Reiterated
03/26/26
Denali Therapeutics price target raised to $35 from $26 at Deutsche BankDenali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Morgan Stanley Analyst forecast on DNLI
Sean Laaman
Morgan Stanley
Morgan Stanley
$40→$42
Buy
104.18%
Upside
Assigned
03/26/26
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Sarepta Therapeutics (NASDAQ: SRPT) and Cardiff Oncology (NASDAQ: CRDF)
William Blair Analyst forecast on DNLI
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/25/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on DNLI
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$29→$31
Buy
50.70%
Upside
Reiterated
03/25/26
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
B. Riley Securities Analyst forecast on DNLI
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$30
Buy
45.84%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Oruka Therapeutics (NASDAQ: ORKA)
Oppenheimer Analyst forecast on DNLI
Jay Olson
Oppenheimer
Oppenheimer
$35
Buy
70.15%
Upside
Reiterated
03/02/26
Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
TD Cowen Analyst forecast on DNLI
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Sandoz Group Ltd (Other OTC: SDZXF)
Wolfe Research Analyst forecast on DNLI
Rudy Li
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
02/23/26
Denali Therapeutics initiated with a Peer Perform at Wolfe ResearchDenali Therapeutics initiated with a Peer Perform at Wolfe Research
UBS Analyst forecast on DNLI
Michael Yee
UBS
UBS
$25
Buy
21.54%
Upside
Initiated
01/06/26
Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DNLI
Charles Moore
Robert W. Baird
Robert W. Baird
$32→$34
Buy
65.29%
Upside
Reiterated
04/07/26
Denali Therapeutics price target raised to $34 from $32 at BairdDenali Therapeutics price target raised to $34 from $32 at Baird
H.C. Wainwright Analyst forecast on DNLI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$95→$42
Buy
104.18%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Fennec Pharmaceuticals (NASDAQ: FENC)
BTIG Analyst forecast on DNLI
Thomas Shrader
BTIG
BTIG
$38→$39
Buy
89.60%
Upside
Assigned
04/06/26
Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
Stifel Nicolaus Analyst forecast on DNLI
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$34→$41
Buy
99.32%
Upside
Reiterated
03/29/26
Stifel Nicolaus Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
Jefferies Analyst forecast on DNLI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$40
Buy
94.46%
Upside
Reiterated
03/26/26
Jefferies Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
Wedbush Analyst forecast on DNLI
Laura Chico
Wedbush
Wedbush
$30
Buy
45.84%
Upside
Reiterated
03/26/26
Wedbush Remains a Buy on Denali Therapeutics (DNLI)
Deutsche Bank Analyst forecast on DNLI
David Hoang
Deutsche Bank
Deutsche Bank
$26→$35
Buy
70.15%
Upside
Reiterated
03/26/26
Denali Therapeutics price target raised to $35 from $26 at Deutsche BankDenali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Morgan Stanley Analyst forecast on DNLI
Sean Laaman
Morgan Stanley
Morgan Stanley
$40→$42
Buy
104.18%
Upside
Assigned
03/26/26
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Sarepta Therapeutics (NASDAQ: SRPT) and Cardiff Oncology (NASDAQ: CRDF)
William Blair Analyst forecast on DNLI
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/25/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on DNLI
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$29→$31
Buy
50.70%
Upside
Reiterated
03/25/26
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
B. Riley Securities Analyst forecast on DNLI
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$30
Buy
45.84%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Oruka Therapeutics (NASDAQ: ORKA)
Oppenheimer Analyst forecast on DNLI
Jay Olson
Oppenheimer
Oppenheimer
$35
Buy
70.15%
Upside
Reiterated
03/02/26
Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)
TD Cowen Analyst forecast on DNLI
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Sandoz Group Ltd (Other OTC: SDZXF)
Wolfe Research Analyst forecast on DNLI
Rudy Li
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
02/23/26
Denali Therapeutics initiated with a Peer Perform at Wolfe ResearchDenali Therapeutics initiated with a Peer Perform at Wolfe Research
UBS Analyst forecast on DNLI
Michael Yee
UBS
UBS
$25
Buy
21.54%
Upside
Initiated
01/06/26
Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

3 Months
xxx
Success Rate
7/12 ratings generated profit
58%
Average Return
+3.82%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +3.82% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
10/17 ratings generated profit
59%
Average Return
+5.75%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +5.75% per trade.
2 Years
xxx
Success Rate
10/17 ratings generated profit
59%
Average Return
+5.90%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +5.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNLI Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
18
16
17
23
22
Buy
7
8
10
13
10
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
24
28
37
33
In the current month, DNLI has received 32 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the past 3 months is 36.27.
Each month's total comprises the sum of three months' worth of ratings.

DNLI Financial Forecast

DNLI Earnings Forecast

Next quarter’s earnings estimate for DNLI is -$0.72 with a range of -$0.86 to -$0.54. The previous quarter’s EPS was -$0.73. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.
Next quarter’s earnings estimate for DNLI is -$0.72 with a range of -$0.86 to -$0.54. The previous quarter’s EPS was -$0.73. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Sales Forecast

Next quarter’s sales forecast for DNLI is $2.57M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $0.00. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.
Next quarter’s sales forecast for DNLI is $2.57M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $0.00. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Stock Forecast FAQ

What is DNLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 36.27.
    What is DNLI’s upside potential, based on the analysts’ average price target?
    Denali Therapeutics has 76.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DNLI a Buy, Sell or Hold?
          Denali Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Denali Therapeutics’s price target?
            The average price target for Denali Therapeutics is 36.27. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $42.00 ,the lowest forecast is $30.00. The average price target represents 76.34% Increase from the current price of $20.57.
              What do analysts say about Denali Therapeutics?
              Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of DNLI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.